Publications Database

Shea S. et al. (2004)

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.

Pediatrics

114(5), e. 634-641

Read Abstract (New Window) Read Full (New Window)

Silva R. R. et al. (1993)

Haloperidol withdrawal and weight changes in autistic children.

Psychopharmacology Bulletin

29(2), pp. 287-291

Read Abstract (New Window)

Stachnik J. M. , Nunn-Thompson C. (2007)

Use of atypical antipsychotics in the treatment of autistic disorder.

Annals of Pharmacotherapy

41(4), pp. 626-634

Read Abstract (New Window)

Stavrakaki C. , Antochi R. , Emery P. C. (2004)

Olanzapine in the treatment of pervasive developmental disorders: a case series analysis.

Journal of Psychiatry and Neuroscience

29(1), pp. 57-60

Read Full (New Window)

Stigler K. A. et al. (2004)

Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.

Pediatric Drugs

6(1), pp. 33-44

Read Abstract (New Window)

Stokstad E. (2008)

Stalled trial for autism highlights dilemma of alternative treatments.

Science

321(5887), p. 326

Read Full (New Window)

Strayhorn J. M. et al. (1998)

Randomized trial of methylphenidate for an autistic child.

Journal of the American Academy of Child and Adolescent Psychiatry

27(2), pp. 244-247

Read Abstract (New Window)

Troost P. et al. (2006)

Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.

Journal of Child and Adolescent Psychopharmacology

pp. 611-619

Read Abstract (New Window)

Troost P. et al. (2005)

Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.

Journal of the American Academy of Child and Adolescent Psychiatry

44(11), pp. 1137-1144

Read Abstract (New Window)

Tsai H. et al. (2012)

Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review.

International Journal of Clinical Practice

November, 66(11), pp. 1056–1078.

Read Abstract (New Window)

Valicenti-McDermott M. R. , Demb H. D. (2006)

Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.

Journal of Child and Adolescent Psychopharmacology

16(5), pp. 549-560

Read Abstract (New Window)

Vo L. C. et al. (2016)

No apparent cardiac conduction effects of acute treatment with risperidone in children with autism spectrum disorder.

Perceptual and Motor Skills

December, 26(10), pp. 900-908

Read Abstract (New Window)

Vyas A. K. , White N. H. (2011)

Case of hypercalcemia secondary to hypervitaminosis a in a 6-year-old boy with autism.

Case Reports in Endocrinology

Read Abstract (New Window) Read Full (New Window)

Ward F. et al. (2013)

Efficacy of beta blockers in the management of problem behaviours in people with intellectual disabilities: a systematic review.

Research in Developmental Disabilities

12, 34 pp. 4293-4303.

Read Abstract (New Window)

Whitehouse A. J. (2013)

Complementary and alternative medicine for autism spectrum disorders: Rationale, safety and efficacy.

Journal of Paediatrics and Child Health

49(9), e. 438-442.

Read Abstract (New Window)

Whitehouse C. , Boullata J. , McCauley L. (2008)

The potential toxicity of artificial sweeteners.

AAOHN Journal

56(6), pp. 251-259

Read Abstract (New Window)

Wink L. K. , Erickson C. A. , McDougle C. J. (2010)

Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders.

Current Treatment Options in Neurology

12(6), pp. 529-538.

Read Abstract (New Window)

Yarbrough E. et al. (1987)

Effects of fenfluramine on autistic individuals residing in a state developmental center.

Journal of Autism and Developmental Disorders

17(3), pp. 303-314

Read Abstract (New Window)

Zuddas A. et al. (2000)

Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.

Journal of Child and Adolescent Psychopharmacology

10(2), pp. 79-90

Read Abstract (New Window)

WebMD (2009)

Secretin.

Web MD

Read Abstract (New Window)